• Precision BioSciences published an updated corporate presentation on its investor website: https://investor.precisionbiosciences.com.
• Deck reiterated ELIMINATE-B biopsy data showing PBGENE-HBV eliminated cccDNA, driving a 1-log (10-fold) drop in cccDNA-derived transcripts.
• Next PBGENE-HBV program update targeted for year-end 2026.
• Deck also noted activation of a second FUNCTION-DMD trial site at Washington University School of Medicine in St. Louis.
• Initial PBGENE-DMD safety data targeted for year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-046340), on July 01, 2026, and is solely responsible for the information contained therein.